Is There A Connection Between Lenalidomide and Second Cancers in Multiple Myeloma?

Lenalidomide (Revlimid, BMS) is a type of immunomodulatory drug or IMiD. It is a core part of modern multiple myeloma treatment. 

While these medications help patients live longer, high-quality research shows they may also increase the risk of developing a secondary cancer. A secondary cancer is a new, unrelated cancer that appears after the original diagnosis.

In this article, you will learn what the research says about lenalidomide and secondary cancer risk and what to ask your doctor.

A large analysis reviewed lenalidomide (Revlimid) in multiple myeloma patients to identify needs and long-term effects

To understand the long-term effects of lenalidomide, researchers reviewed 25 different clinical trials involving 10,743 patients. This large study focused on what happens when patients take the drug for at least six months as part of their initial treatment and long-term maintenance.

The findings showed that while lenalidomide is a "backbone" of myeloma care, it does come with risks that become more important as patients live longer:

• Second cancers: The study found a 5% overall rate of new cancers. This included a 4% rate of solid tumors (like lung or skin cancer) and a 2% rate of blood-related cancers.
• Blood clot risks: Researchers found that 4% of patients experienced venous thrombosis (clots in the veins), while about 1% experienced arterial thrombosis (clots in the arteries).
• The need for monitoring: Because these events are more likely as survival times increase, the study suggests that patients on long-term maintenance should have an active program to monitor and treat these side effects early.

Why the risk varies across different diseases

A separate review looked at 14,058 patients. The study wanted to understand if lenalidomide caused second cancers in everyone who took the medication. The results helped put the risk into perspective for myeloma patients.

The study compared patients with different types of diseases and found the following:

• Unique to myeloma: The increased risk of a second cancer was found only in patients with multiple myeloma.
• Safety in other diseases: Patients taking the lenalidomide for lymphoma or chronic lymphocytic leukemia (CLL) did not show an increased risk of second cancers.
• Possible reasons: Researchers noted that myeloma might cause changes in the body that make it easier for the drug to have this side effect. Another possible cause is that other myeloma-specific drugs used in combination might play a role. More research is needed to understand why lenalidomide causes second cancers in myeloma.
• A new standard for care: This research teaches the medical community that the effects of a drug can change depending on the specific disease being treated. It also reminds doctors to look for both blood cancers and solid tumors during follow-up care.

Ask your doctor about possible warning signs and monitoring for second cancers

Lenalidomide remains a cornerstone of treatment that has helped many people with multiple myeloma live longer, fuller lives. While there is a small but real risk of second cancers and blood clots, being aware of this allows you and your doctors to stay one step ahead. By combining effective myeloma treatment with active monitoring, you can focus on your recovery while protecting your long-term health.

Being proactive as a patient can involve continuing with all scheduled blood tests and check-ups, even if you have been in remission for years. Another important part of being proactive is always telling your healthcare team about any new or unusual changes, such as new bone pain, extreme fatigue, or changes in urinary habits. 

You can also keep track of your lab values, and notice when something is unusual, even if you don’t have symptoms. If you receive care in more than one center, you can track it all in one place with HealthTree. 

By securely connecting your records you can have all your information in one place, even if it’s from different facilities. 

CREATE YOUR ACCOUNT 

Sources: 

• Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

• Lenalidomide-Associated Risk for SPMs Appear Isolated to MM